KLRB1 and esophageal squamous cell carcinoma: Transcription of KLRB1 was suppressed in 68% of NSCLC (non-small cell lung cancer) and 57% of esophageal squamous-cell carcinoma patients indicating that CD161 can be a predictive marker in these indications (74).